2020 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards

Emmanuel J. Favaloro

doi:10.1055/s-0041-1724120

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2021; 47(03): 229-237
DOI: 10.1055/s-0041-1724120

Editorial

2020 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards

Autor*innen

Emmanuel J. Favaloro

¹Sydney Centres for Thrombosis and Haemostasis, Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, Australia

Abstract

Volltext

Referenzen

References
1 Favaloro EJ. 2020 Eberhard F. Mammen Award announcements: part I-most popular articles. Semin Thromb Hemost 2020; 46 (04) 383-392
2 Tay J, Tiao J, Hughes Q, Jorritsma J, Gilmore G, Baker R. Circulating microRNA as thrombosis sentinels: caveats and considerations. Semin Thromb Hemost 2018; 44 (03) 206-215
3 Klil-Drori AJ, Tagalakis V. Direct oral anticoagulants in end-stage renal disease. Semin Thromb Hemost 2018; 44 (04) 353-363
4 van Asten I, Schutgens REG, Urbanus RT. Toward flow cytometry based platelet function diagnostics. Semin Thromb Hemost 2018; 44 (03) 197-205
5 Laridan E, Martinod K, De Meyer SF. Neutrophil extracellular traps in arterial and venous thrombosis. Semin Thromb Hemost 2019; 45 (01) 86-93
6 Blennerhassett R, Curnow J, Pasalic L. Immune-mediated thrombotic thrombocytopenic purpura: a narrative review of diagnosis and treatment in adults. Semin Thromb Hemost 2020; 46 (03) 289-301
7 Brennan Y, Favaloro EJ, Curnow J. To maintain or cease non-vitamin K antagonist oral anticoagulants prior to minimal bleeding risk procedures: a review of evidence and recommendations. Semin Thromb Hemost 2019; 45 (02) 171-179
8 Schreuder M, Reitsma PH, Bos MHA. Reversal agents for the direct factor Xa inhibitors: biochemical mechanisms of current and newly emerging therapies. Semin Thromb Hemost 2020; 46 (08) 986-998
9 Stevens H, McFadyen JD. Platelets as central actors in thrombosis-reprising an old role and defining a new character. Semin Thromb Hemost 2019; 45 (08) 802-809
10 Zolkova J, Sokol J, Simurda T. et al. Genetic background of von Willebrand disease: history, current state, and future perspectives. Semin Thromb Hemost 2020; 46 (04) 484-500
11 Bolek T, Samoš M, Škorňová I. et al. Proton pump inhibitors and dabigatran therapy: impact on gastric bleeding and dabigatran plasma levels. Semin Thromb Hemost 2019; 45 (08) 846-850
12 Danese E, Montagnana M, Gelati M, Lippi G. The role of epigenetics in the regulation of hemostatic balance. Semin Thromb Hemost 2020; 47 (01) 53-62
13 Douxfils J, Morimont L, Bouvy C. Oral contraceptives and venous thromboembolism: focus on testing that may enable prediction and assessment of the risk. Semin Thromb Hemost 2020; 46 (08) 872-886
14 Boon GJAM, Huisman MV, Klok FA. Why, whom, and how to screen for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Semin Thromb Hemost 2020; ( e-pub ahead of print).
15 Khialani D, Rosendaal F, Vlieg AVH. Hormonal contraceptives and the risk of venous thrombosis. Semin Thromb Hemost 2020; 46 (08) 865-871